

**Corrigendum****Effects of Risperidone Augmentation in Patients with Treatment-Resistant Depression: Results of Open-Label Treatment Followed by Double-Blind Continuation**

**Mark Hyman Rapaport, Georges M Gharabawi, Carla M Canuso, Ramy A Mahmoud, Martin B Keller, Cynthia A Bossie, Ibrahim Turkoz, Robert A Lasser, Amy Loescher, Philippe Bouhours, Fiona Dunbar and Charles B Nemeroff**

*Neuropsychopharmacology* (2007) **32**, 1208. doi:10.1038/sj.npp.1301322

**Correction to:** *Neuropsychopharmacology* (2006) **31**, 2505–2513. doi:10.1038/sj.npp.1301113

Following the publication of this article, the authors noted that in the abstract and in the next to last paragraph of the results section, a *P*-value for part of one of the *post hoc* analyses was incorrectly reported. A significant *P*-value was reported for both the difference in time to relapse and for

relapse rates in a subgroup of patients fully non-responsive to citalopram monotherapy. Although the *P*-value for time to relapse was correctly reported, the correct *P*-value for the comparison of relapse rates is not significant ( $P = 0.4$ ; CMH test). This change does not alter the major findings of the study nor any of the conclusions of the report. We appreciate the assistance of a diligent reader in identifying this error.